{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%28Copegus%C2%AE%29", "query": { "intervention": "Ribavirin (Copegus®)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 113, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%28Copegus%C2%AE%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T00:46:38.503Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02292706", "title": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" }, { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "Other SOF-Based Regimen", "type": "DRUG" }, { "name": "Ineligible parent treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1609, "start_date": "2014-12-29", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292706" }, { "nct_id": "NCT01858766", "title": "Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2013-04", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 50, "location_summary": "La Jolla, California • Long Beach, California • Los Angeles, California + 38 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858766" }, { "nct_id": "NCT02994056", "title": "Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-01-23", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 10, "location_summary": "Tampa, Florida • Chicago, Illinois • Catonsville, Maryland + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Catonsville", "state": "Maryland" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02994056" }, { "nct_id": "NCT00863239", "title": "Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "ribavirin", "type": "DRUG" }, { "name": "Locteron™ (controlled-release interferon alpha 2b)", "type": "DRUG" }, { "name": "PEG-Intron™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biolex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 116, "start_date": "2009-03", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-02-02", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 13, "location_summary": "Chula Vista, California • Oceanside, California • San Diego, California + 10 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Laurel", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863239" }, { "nct_id": "NCT02716428", "title": "A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Viral Infection", "Chronic Hepatitis C", "Hepatitis C (HCV)", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "Faldaprevir", "type": "DRUG" }, { "name": "TD-6450", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trek Therapeutics, PBC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2016-05", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 3, "location_summary": "Coronado, California • Bradenton, Florida • Germantown, Tennessee", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716428" }, { "nct_id": "NCT01808248", "title": "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2013-02", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01808248" }, { "nct_id": "NCT02094443", "title": "Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2014-03", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-10-13", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 11, "location_summary": "Bakersfield, California • Lancaster, California • San Diego, California + 6 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02094443" }, { "nct_id": "NCT02536313", "title": "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2015-07-29", "completion_date": "2016-06-28", "has_results": true, "last_update_posted_date": "2019-02-25", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02536313" }, { "nct_id": "NCT01467492", "title": "Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 121, "start_date": "2012-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-03", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 27, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467492" }, { "nct_id": "NCT01435044", "title": "Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "GS-0938", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Placebo to match sofosbuvir", "type": "DRUG" }, { "name": "Placebo to match GS-0938", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2011-09", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-29T00:46:38.503Z", "location_count": 42, "location_summary": "Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01435044" } ] }